Published in Blood on July 15, 1991
Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. Biophys J (2001) 2.86
Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest (1993) 2.00
Grow with the flow: a spatial-temporal model of platelet deposition and blood coagulation under flow. Math Med Biol (2010) 1.47
Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol (2007) 1.34
Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed) (2012) 1.28
Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice. J Thromb Haemost (2009) 1.20
TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Blood (2011) 1.10
Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition. J Thromb Haemost (2007) 1.08
The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci U S A (1994) 1.08
Biology of tissue factor pathway inhibitor. Blood (2014) 1.01
Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A (2013) 1.01
Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest (1999) 1.00
Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth. Arterioscler Thromb Vasc Biol (2011) 0.99
Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. J Clin Pharmacol (2007) 0.94
A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor. J Matern Fetal Neonatal Med (2008) 0.90
Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol (2009) 0.90
How it all starts: Initiation of the clotting cascade. Crit Rev Biochem Mol Biol (2015) 0.87
Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci (2008) 0.86
Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J (1997) 0.86
Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol (2013) 0.84
Tissue factor pathway inhibitor in childhood nephrotic syndrome. Pediatr Nephrol (2006) 0.81
Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. Thromb Res (2009) 0.81
Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor. Biochem J (2012) 0.81
Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well? Curr Cardiol Rev (2010) 0.80
Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits. J Clin Invest (1996) 0.79
Plasma tissue factor pathway inhibitor levels in patients with acute pancreatitis. J Gastroenterol (2009) 0.79
Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein. Arterioscler Thromb Vasc Biol (2015) 0.77
Flow-simulated thrombin generation profiles as a predictor of thrombotic risk among pre-menopausal women. Thromb Haemost (2012) 0.76
A Mathematical Model of Venous Thrombosis Initiation. Biophys J (2016) 0.75
Targeting TFPI for hemophilia treatment. Thromb Res (2016) 0.75
Platelet full length TFPI-α in healthy volunteers is not affected by sex or hormonal use. PLoS One (2017) 0.75
Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins. Br J Haematol (2016) 0.75
Computational Study of Thrombus Formation and Clotting Factor Effects under Venous Flow Conditions. Biophys J (2016) 0.75
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med (1995) 3.88
Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc (1999) 3.32
Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation (1997) 3.23
Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet (1994) 3.22
Factor XI activation in a revised model of blood coagulation. Science (1991) 2.87
Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation (1999) 2.84
A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med (1995) 2.65
Properties of the factor Xa binding site on human platelets. J Biol Chem (1978) 2.59
A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet (1999) 2.56
Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest (1999) 2.54
Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science (1992) 2.24
Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem (1988) 2.09
Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature (1989) 2.07
Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature (1993) 2.05
The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest (2001) 2.04
Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci U S A (1977) 2.03
Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol (2000) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med (1998) 1.98
Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA (1997) 1.94
Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood (1997) 1.94
The synthesis of sulfated dextran beads for isolation of human plasma coagulation factors II, IX, and X. Anal Biochem (1980) 1.89
G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation (1999) 1.72
Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood (1988) 1.72
The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J Clin Invest (1997) 1.67
Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation (1997) 1.63
Purification and properties of human coagulation factor VII. J Biol Chem (1980) 1.61
Binding of human factor VII and VIIa to monocytes. J Clin Invest (1982) 1.60
MDR and PRP: a comparison of methods for high-order genotype-phenotype associations. Hum Hered (2004) 1.59
Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science (1990) 1.56
Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci U S A (1998) 1.55
Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood (1996) 1.50
A murine model of factor XI deficiency. Blood Coagul Fibrinolysis (1997) 1.49
Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood (1992) 1.46
Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem (1998) 1.46
Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation (2001) 1.46
Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem (2000) 1.45
Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem (1989) 1.45
Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol (2000) 1.43
Human tissue factor: cDNA sequence and chromosome localization of the gene. Biochemistry (1987) 1.43
Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J Clin Invest (1978) 1.42
The protein Z-dependent protease inhibitor is a serpin. Biochemistry (1999) 1.41
Characterization of the protein Z-dependent protease inhibitor. Blood (2000) 1.41
Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J Lipid Res (1999) 1.40
Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood (1996) 1.39
Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein. Thromb Res (1989) 1.37
Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb Haemost (2001) 1.36
Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation (2001) 1.35
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost (2001) 1.33
Mixed modelling to characterize genotype-phenotype associations. Stat Med (2005) 1.31
Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood (2001) 1.30
Human Protein Z. J Clin Invest (1984) 1.28
Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation (1995) 1.24
Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem (1993) 1.23
Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem (2001) 1.23
The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood (1992) 1.22
Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A (2000) 1.21
Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder. Blood (1979) 1.20
Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci U S A (1997) 1.17
Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood (1991) 1.17
Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (1999) 1.16
Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis (1989) 1.15
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem (2001) 1.12
Beta protein C is not glycosylated at asparagine 329. The rate of translation may influence the frequency of usage at asparagine-X-cysteine sites. J Biol Chem (1990) 1.11
Human plasma protein Z antigen: range in normal subjects and effect of warfarin therapy. Blood (1987) 1.11
Inflammatory markers of coronary risk. N Engl J Med (2000) 1.10
Characterization of the inhibition of tissue factor in serum. Blood (1987) 1.10
Selectivity of diadenosine polyphosphates for rat P2X receptor subunits. Eur J Pharmacol (1999) 1.10
Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost (2005) 1.09
Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis (1993) 1.08
Purification of human brain tissue factor. J Biol Chem (1985) 1.08
The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci U S A (1994) 1.08
Plate fixation of iliac shaft fractures in the dog. J Am Vet Med Assoc (1975) 1.07
Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med (1998) 1.06
Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg (1996) 1.06
Relationships between platelets and coagulation factors in hemostasis. Annu Rev Med (1978) 1.06
Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol Ther (2000) 1.05
Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. J Lipid Res (2000) 1.05
Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest (1993) 1.03
Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation (2001) 1.03
ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest (1999) 1.03
Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci U S A (1987) 1.02